EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A single‐centre analysis of a biosimilar switching programme for adalimumab in inflammatory bowel disease

Louise Rabbitt iD, Áine Keogh, Linda Duane, John Ferguson, Anna Hobbins, Brian E McGuire, Patrick Gillespie, Laurence J Egan

British Journal of Clinical Pharmacology · 2025

DOI: 10.1002/bcp.70086 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Louise Rabbitt und 7 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Pharmacology and Therapeutics, School of Medicine, University of Galway, Ireland. Hauptthemen laut MEDLINE: Adalimumab, Biosimilar Pharmaceuticals, Drug Substitution, Colitis, Ulcerative. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Health and Social Care, Research and Development Division, Northern Ireland, Health Service Executive, National Doctors Training and Planning.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Amgevita is a licensed biosimilar to adalimumab, having demonstrated high pharmacokinetic and clinical similarity to Humira. Switching to a lower‐cost medicine may elicit a nocebo effect, whereby expectations of poorer efficacy impact outcomes despite pharmacological similarity. This prospective cohort study examined clinical and economic outcomes and associated psychosocial variables in a group of patients undergoing a nonmedical switch to biosimilar adalimumab.

Methods

Patients with inflammatory bowel disease (IBD) were followed before and after switching from Humira to Amgevita. Objective disease activity was assessed pre‐ and post‐switch using the Harvey–Bradshaw Index (Crohn's disease) or partial Mayo score (ulcerative colitis), faecal calprotectin and C‐reactive protein. Subjective symptom burden was measured using the IBD Control Questionnaire (IBDCQ). Pre‐switch, health anxiety was measured using the Health Anxiety Index (HAI).

Results

In total, 64 patients aged 18–67 were enrolled. IBDCQ scores marginally improved post‐switch (13.33 vs , 12.49, P = .043), with no significant changes in objective disease activity scores, faecal calprotectin or C‐reactive protein. Sixteen patients reported 17 new adverse events within 4 weeks. Logistic regression revealed a significant relationship between HAI scores and adverse events ( P = .0079); each unit increase in HAI score increased the odds of reporting an adverse event by 21%. Drug cost savings for the 64 patients over 8 weeks totalled €143 958.

Conclusion

Switching to biosimilar adalimumab did not affect disease control or quality of life. 25% of patients developed new side effects, particularly those with high levels of health anxiety. Significant cost savings were achieved.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdalimumabBiosimilar PharmaceuticalsDrug SubstitutionColitis, UlcerativeCrohn DiseaseInflammatory Bowel DiseasesHumansFemaleMaleAdultMiddle AgedProspective StudiesAgedYoung AdultAdolescentLeukocyte L1 Antigen ComplexSeverity of Illness IndexTreatment OutcomeFecesC-Reactive ProteinAnxiety

Stichwörter der Autor:innen

adalimumabbiosimilarhealth economicsinflammatory bowel diseasenocebo

Substanzen

AdalimumabBiosimilar PharmaceuticalsLeukocyte L1 Antigen ComplexC-Reactive Protein

Autor:innen und Institutionen

  • Discipline of Pharmacology and Therapeutics, School of Medicine, University of Galway, Ireland.
  • Department of Gastroenterology, Galway University Hospitals, Galway, Ireland.
  • School of Mathematical and Statistical Sciences, University of Galway, Ireland.
  • Research Ireland Centre for Medical Devices (CÚRAM, 13/RC/2073_P2), Ireland.
  • Health Economics & Policy Analysis Centre (HEPAC), Institute for Lifecourse & Society (ILAS), University of Galway, Ireland.
  • School of Psychology & Centre for Pain Research, University of Galway, Ireland.

ORCID-Profile: Louise Rabbitt

Förderung

  • Wellcome Trust
  • Health and Social Care, Research and Development Division, Northern Ireland
  • Health Service Executive, National Doctors Training and Planning

Zitieren

APA

Rabbitt, L., Keogh, Á., Duane, L., Ferguson, J., Hobbins, A., McGuire, B. E., Gillespie, P., & Egan, L. J. (2025). A single‐centre analysis of a biosimilar switching programme for adalimumab in inflammatory bowel disease. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70086

Vancouver

Rabbitt L, Keogh Á, Duane L, Ferguson J, Hobbins A, McGuire BE, et al. A single‐centre analysis of a biosimilar switching programme for adalimumab in inflammatory bowel disease. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70086

BibTeX
@article{Rabbitt2025,
  author = {Rabbitt, Louise and Keogh, Áine and Duane, Linda and Ferguson, John and Hobbins, Anna and McGuire, Brian E and Gillespie, Patrick and Egan, Laurence J},
  title = {A single‐centre analysis of a biosimilar switching programme for adalimumab in inflammatory bowel disease},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/bcp.70086}
}
Kostenlos starten →